iiinova — where your digital self keeps evolving

Martin Schostak MD, PhD @martin-schostak.bsky.social · 03/10/2026

🏆 Was für eine wunderbare Ehrung! Die #DGU hat mir den #Ritter-von-Frisch-Preis verliehen. Ich freue mich riesig! 😊🙏 ❤️ Danke an Prof. Susanne Krege, @axelmerseburger.bsky.social und viele großartige Wegbegleiter! Gemeinsam macht Urologie Spaß! 🚀🥂 #RittervonFrischPreis #Urologie #DGU2026#LOGICURO

Axel Merseburger und sein Team freuen sich mit mir auf dem DGU-Festabend

010

Martin Schostak MD, PhD @martin-schostak.bsky.social · 31/08/2026

Fokale Therapie - Fortschritt oder Illusion? 🎯 Nach 20 Jahren endlich im Standard angekommen und doch am Scheideweg - Präzisionsmedizin braucht Evidenz – und eine Finanzierung, die sie ermöglicht. 🔬💶 Akt Urol 2026; 57: 471–478

010

Reposted by Martin Schostak MD, PhD

The Advanced Prostate Cancer Consensus Conference @apccc.bsky.social · 26/03/2025

Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial jamanetwork.com/journals/jam... These findings suggest that microultrasonography could serve as an alternative to MRI for prostate cancer diagnosis. #ProstateCancer

jamanetwork.com

Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis

This randomized, noninferiority trial of biopsy-naive men compares the detection of Gleason Grade Group ≥2 prostate cancer using microultrasonography-guided and MRI fusion-guided biopsy.

074

Martin Schostak MD, PhD @martin-schostak.bsky.social · 24/03/2025

Proud to be one of the investigators: #MicroUS noninferior to MRI fusion for csPCa (46.1% vs 42.6%)! No MRI, slightly better results. 802 pts, 8 countries. Just presented #EAU25 and published in #JAMA. #ProstateCancer #biopsy @axelmerseburger.bsky.social

371

Martin Schostak MD, PhD @martin-schostak.bsky.social · 24/03/2025

LATP hits harder: +5.7% GG≥2 vs TRUS (p=0.031)! Fewer infections, slightly more pain & embarrassment. No abx needed. Costlier, slower—but sharper. #TRANSLATEtrial #ProstateCancer #LATP #TRUS #EAU25 #LancetOncology @axelmerseburger.bsky.social

041

Reposted by Martin Schostak MD, PhD

Tian Zhang, MD @tiansterzhangmd.bsky.social · 14/02/2025

@erplimackmd.bsky.social with killer discussion setting the scene for the #NIAGARA “sandwich” & #Checkmate274, both practice changing for our pts w #bladdercancer. @ascocancer.bsky.social #GU25

193

Martin Schostak MD, PhD @martin-schostak.bsky.social · 08/02/2025

🚀 Excited for #ASCOGU25! Looking forward to groundbreaking insights and game-changers once again! 🔬 Can't wait to see what’s ahead. 🎯 Stay tuned! #UroOncology #GameChanger @axelmerseburger.bsky.social

031

Martin Schostak MD, PhD @martin-schostak.bsky.social · 08/02/2025

🔥 #TestisCancer highlight from #ASCOGU! 📌 Abstract 618 – Final results of the #COTRIMS trial: Retroperitoneal lymphadenectomy in metastatic #Seminoma. Important data for #GermCellTumors! What’s your take?

020

Martin Schostak MD, PhD @martin-schostak.bsky.social · 08/02/2025

🚀 Key #UrothelialCancer abstracts from #ASCOGU! 📌 Abstract 661 – #Durvalumab (#MEDI4736) + neoadjuvant chemo (#Gemcitabine + #Cisplatin / #Carboplatin) in high-risk upper tract urothelial carcinoma. 📌 Abstract 667 – #Durvalumab + intravesical #Gemcitabine & #Docetaxel in #BCG-unresponsive NMIBC.

020

Martin Schostak MD, PhD @martin-schostak.bsky.social · 08/02/2025

🔥 Exciting #ProstateCancer Abstracts from #ASCOGU: 📌 LBA18 – Final overall survival results of the phase 3 #TALAPRO2 trial. 📌 Abstract 21 – Transdermal #Estradiol (#tE2) patches + #ARPIs in metastatic (#M1) prostate cancer. 📌 Abstract 22 – #Metastases-directed therapy in oligometastatic #CRPC.

010

Reposted by Martin Schostak MD, PhD

Yale Cancer Center @yalecancer.bsky.social · 05/02/2025

Patients receiving a personalized cancer vaccine #PCV for #renalcellcarcinoma remained cancer-free after 40 months, according to a phase 1 study led by Dr. David Braun and @danafarber.bsky.social colleagues published today in #Nature. yalecancercenter.org/news-article...

yalecancercenter.org

Personalized therapeutic vaccine ‘steers’ the immune system to fight kidney cancer

Vaccines are on the cutting edge of cancer therapy research as a possible treatment option for the future. The trial led by Yale Cancer Center (YCC) principal

0102

Reposted by Martin Schostak MD, PhD

Toni Choueiri, MD @drchoueiri.bsky.social · 05/02/2025

Our paper in @nature.com is finally published: a prospective trial of a personalized Neoantigen Vaccine in Kidney Cancer www.nature.com/articles/s41... This is teamwork with @danafarber.bsky.social @yalecancer.bsky.social @harvardmed.bsky.social + Wu lab www.nature.com/articles/s41...

12915

Reposted by Martin Schostak MD, PhD

Yüksel Ürün @yukselurun.bsky.social · 20/01/2025

🔵1 in 3 men experience PSA persistence or relapse within 10 years post-radical prostatectomy. 🔵Early relapse (<2 years) = higher PCa death risk (8.5%) vs. late relapse (>5 years, 1.4%). 🔵Life expectancy and relapse timing guide treatment. #ProstateCancer #Oncology @oncoalert.bsky.social

183

Reposted by Martin Schostak MD, PhD

Yüksel Ürün @yukselurun.bsky.social · 04/01/2025

🧬💊2024 FDA approvals highlight cancer as a priority: 15 (30%) novel drugs, including the 11th PD1/PDL1 blocker. 🎯 Our mission is clear: ensure the right treatment is available and accessible to every patient. Equity in care is non-negotiable. @oncoalert.bsky.social @oncbrothers.bsky.social

032

Reposted by Martin Schostak MD, PhD

Chris Hendel @chrishendel.bsky.social · 27/12/2024

THE best presentation of study figures ever! 😆 "We presented scaled versions of this puzzle to both people and ants (Fig. 1 A and B)." per Proceedings of the National Academy of Sciences @pnas.org www.pnas.org/doi/10.1073/...

48922

Reposted by Martin Schostak MD, PhD

Alvaro Pinto @dralvaropinto.bsky.social · 27/12/2024

“FDA Approves Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors”. Great news for patients, more convenient treatments, and less time- and resource-consuming schedules. www.onclive.com/view/fda-app...

onclive.com

FDA Approves Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors

The FDA has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult solid tumor nivolumab (Opdivo) indications.

021

Reposted by Martin Schostak MD, PhD

Sabine D. Brookman-May, MD, FEBU🚴‍♀️🚴‍♀️🚴‍♀️🏔️⛷️⛰️ @brookmans76.bsky.social · 08/12/2024

#Nectin4 in GU vs other malignancies ✅ Nectin4 is more prevalent in GU cancers than others ✅ still more data needed on the prognostic and predictive value 👉 Interested in more data on how prior treatment impacts Nectin4 + how this could impact treatment sequence @oncodaily.bsky.social #BladderCancer

071

Reposted by Martin Schostak MD, PhD

Yüksel Ürün @yukselurun.bsky.social · 24/12/2024

Adjuvant nivolumab continues to show significant benefits in MIUC. At 36.1 months, DFS & OS improved in ITT (DFS HR 0.71, OS HR 0.76) and PD-L1 ≥1% (DFS HR 0.52, OS HR 0.56). No new safety signals. #oncology #cancer @oncoalert.bsky.social doi.org/10.1200/JCO....

072

Martin Schostak MD, PhD @martin-schostak.bsky.social · 23/12/2024

Wieso ist der #X-Account des #Magdeburg-Attentäters mit fast 50.000 Followern nach über drei Tagen noch immer online? Wenn die #Plattform #X schon nicht agiert, vielleicht sogar, weil ihr Chef eine solche „Meinungsfreiheit“ unterstützt, warum tut das BKA oder das Innenministerium denn auch nichts?

010

Reposted by Martin Schostak MD, PhD

JAMA @jama.com · 22/12/2024

Initial active surveillance and watchful waiting significantly increased for intermediate–risk prostate cancer between 2010 and 2020. ja.ma/4042hPZ

Figure. Time Trends in the Initial Selection of Active Surveillance and Watchful Waiting Among Individuals With Intermediate-Risk Prostate Cancer

0137

Martin Schostak MD, PhD @martin-schostak.bsky.social · 23/12/2024

I am not only leaving the University of #Magdeburg but also #X You can now find me here and at logicuro.com

120

Martin Schostak MD, PhD @martin-schostak.bsky.social · 22/12/2024

Genug ist genug! #Musk missbraucht seine Plattform zur Unterstützung Radikaler. Nach 10 Jahren auf #X bin ich raus! Hallo an alle hier auf #Bluesky! 👋

010

Reposted by Martin Schostak MD, PhD

Erik Marquardt @erik-marquardt.eu · 21/12/2024

Elon Musk sollte nach diesem schrecklichen Attentat in Magdeburg endlich zur Rechenschaft gezogen werden. Der Attentäter hat offenbar Straftaten auf X angekündigt. Plattformbetreiber sind rechtlich dazu verpflichtet, das Behörden zu melden. Warum ist das nicht geschehen?

20664144

Martin Schostak MD, PhD @martin-schostak.bsky.social · 21/12/2024

Enough is enough! I refuse to support dictators, racists, and radicals. After 10 years on Twitter, I'm done! Hello everyone on Bluesky!

020

Martin Schostak MD, PhD @martin-schostak.bsky.social · 19/12/2024

Ich verlasse nicht nur die Uni #Magdeburg, sondern auch #X – weil es jetzt einfach reicht! Ab sofort findet ihr mich hier und unter logicuro.com @axelmerseburger.bsky.social

051